Investigational drug · Phase 2
SAL0140
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Aldosteronism, Chronic Kidney Disease, Uncontrolled Hypertension.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "SAL0140"
First trial start
2025
Dec 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAL0140", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Aldosteronism
- Chronic Kidney Disease
- Uncontrolled Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "SAL0140" as an intervention, largest first.
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled HypertensionPivotal-lookingRecruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07654140 · 252 participants (planned) · Start Dec 9, 2025 · Primary completion Mar 1, 2027
Drug: SAL0140; SAL0140 and 2 more · For: Uncontrolled Hypertension
Sites: Beijing, China
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney DiseasePivotal-lookingNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07647133 · 249 participants (planned) · Start Jun 15, 2026 · Primary completion Oct 8, 2027
Drug: SAL0140 Tablets; SAL0140 Tablets and 1 more · For: Chronic Kidney Disease
Sites: Shenzhen, China; Nanjing, China
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07051603 · 82 participants (planned) · Start Jun 9, 2025 · Primary completion Jan 2026
Drug: SAL0140; SAL0140 placebo · For: Uncontrolled Hypertension
Sites: Guangzhou, China
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismNot yet recruiting
Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
NCT07646535 · 50 participants (planned) · Start Jun 12, 2026 · Primary completion Apr 1, 2027
Drug: SAL0140 Tablets; SAL0140 Tablets and 1 more · For: Primary Aldosteronism
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Primary Aldosteronism
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
- SYH2072Phase 22 trials
InnovStone Therapeutics Limited · Uncontrolled Hypertension, Resistant Hypertension, Primary Aldosteronism
- QLS1410Phase 21 trial
Qilu Pharmaceutical Co., Ltd. · Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.